


What is claimed is:

1. A compound represented by formula (II), an (*R*)-isomer thereof, an (*S*)-isomer thereof or a pharmaceutically acceptable salt thereof,




wherein,

 is a single bond or a double bond;

R₁ is selected from H and C₁₋₃ alkyl, wherein the C₁₋₃ alkyl is optionally substituted by R, and the number of R is 1, 2 or 3;

R₅ is selected from H and C₁₋₃ alkyl, wherein the C₁₋₃ alkyl is optionally substituted by R, and the number of R is 1, 2 or 3;

R₆ is selected from R₆₁,



r is 1 or 2;

m is 1 or 2;

D is selected from -N(R₂)-, -N⁺(O⁻)(R₂)- and -C(R₃)(R₄)-;

R₂ is selected from H and C₁₋₃ alkyl, wherein the C₁₋₃ alkyl is optionally substituted by R, and the number of R is 1, 2 or 3;

R₃ and R₄ are independently selected from H, F, Cl, Br, I, OH, NH₂ and C₁₋₃ alkyl, wherein the NH₂ and the C₁₋₃ alkyl are optionally substituted by R, and the number of R is 1, 2 or 3;

alternatively, R₃ and R₄ together with the carbon atom to which they are attached form a 5-7 membered cycloalkyl or 5-7 membered heterocycloalkyl, wherein the 5-7 membered cycloalkyl and 5-7 membered heterocycloalkyl are optionally substituted by R, and the number of R is 1, 2 or 3;

R₆₁ is selected from H, F, Cl, Br, I, OH, NH₂, C₁₋₃ alkoxy and -O-C₃₋₆ cycloalkyl, wherein the C₁₋₃ alkoxy and the -O-C₃₋₆ cycloalkyl are optionally substituted by R, and the number of R is 1, 2 or 3;

R₇ is selected from H, F, Cl, Br, I, OH, NH₂, C₁₋₃ alkyl, C₁₋₃ alkoxy and 5-6 membered heterocycloalkyl, wherein the C₁₋₃ alkyl, C₁₋₃ alkoxy and 5-6 membered heterocycloalkyl are optionally substituted by R, and the number of R is 1, 2 or 3;

alternatively, R₆ and R₇ together with the ring atoms to which they are attached form ring A, and the ring A is selected from 5-7 membered heterocycloalkyl which is optionally substituted by R, and the number of R is 1, 2 or 3;

R is independently selected from F, Cl, Br, I, OH, NH₂, C₁₋₃ alkyl, C₁₋₃ alkoxy and C₁₋₃ alkylamino; the 5-7 membered heterocycloalkyl contains 1, 2, 3 or 4 heteroatoms or heteroatom groups independently selected from -NH-, -S- and N.

2. The compound, the (*R*)-isomer thereof, the (*S*)-isomer thereof or the pharmaceutically acceptable salt thereof as defined in claim 1, wherein the R is independently selected from F, Cl, Br, I, OH,

NH₂, CH₃, Et, -OCH₃ and .

3. The compound, the (*R*)-isomer thereof, the (*S*)-isomer thereof or the pharmaceutically acceptable salt thereof as defined in claim 1 or 2, wherein the R₁ is selected from H, CH₃ and Et.

4. The compound, the (*R*)-isomer thereof, the (*S*)-isomer thereof or the pharmaceutically acceptable salt thereof as defined in claim 1 or 2, wherein the R₂ is selected from H, CH₃ and Et.

5. The compound, the (*R*)-isomer thereof, the (*S*)-isomer thereof or the pharmaceutically acceptable salt thereof as defined in claim 1 or 2, wherein the R₃ and R₄ are independently selected from H, F, Cl, Br, I, OH, NH₂, -NH(CH₃), -N(CH₃)₂, CH₃ and Et.





6. The compound, the (*R*)-isomer thereof, the (*S*)-isomer thereof or the pharmaceutically acceptable salt thereof as defined in claim 5, wherein the R₃ is selected from H, F, Cl, Br, I, OH, NH₂, -NH(CH₃), -N(CH₃)₂, CH₃ and Et.

7. The compound, the (*R*)-isomer thereof, the (*S*)-isomer thereof or the pharmaceutically acceptable salt thereof as defined in claim 5, wherein the R₄ is selected from H, F, Cl, Br, I, OH, CH₃ and Et.


8. The compound, the (*R*)-isomer thereof, the (*S*)-isomer thereof or the pharmaceutically acceptable salt thereof as defined in claim 1 or 2, wherein the R₅ is selected from H, CH₃ and Et, wherein the CH₃ and Et are optionally substituted by R, and the number of R is 1, 2 or 3.

9. The compound, the (*R*)-isomer thereof, the (*S*)-isomer thereof or the pharmaceutically acceptable salt thereof as defined in claim 8, wherein the R₅ is selected from H, CH₃ and -CH₂OH.


10. The compound, the (*R*)-isomer thereof, the (*S*)-isomer thereof or the pharmaceutically acceptable salt thereof as defined in claim 1 or 2, wherein the R₆₁ is selected from H, F, Cl, Br, I,


OH, NH₂, -OCH₃,  and , wherein the -OCH₃,  and  are optionally substituted by R, and the number of R is 1, 2 or 3.

11. The compound, the (*R*)-isomer thereof, the (*S*)-isomer thereof or the pharmaceutically acceptable salt thereof as defined in claim 10, wherein the R₆₁ is selected from H, F, Cl, Br, I, OH, NH₂, -OCH₃,






12. The compound, the (*R*)-isomer thereof, the (*S*)-isomer thereof or the pharmaceutically

acceptable salt thereof as defined in claim 1 or 2, wherein the R₆ is selected from R₆₁, ,




13. The compound, the (*R*)-isomer thereof, the (*S*)-isomer thereof or the pharmaceutically

acceptable salt thereof as defined in claim 12, wherein the R₆ is selected from R₆₁, , ,




14. The compound, the (*R*)-isomer thereof, the (*S*)-isomer thereof or the pharmaceutically acceptable salt thereof as defined in claim 1, wherein the R₃ and R₄ together with the carbon atom to which they are attached form a 5-7 membered cycloalkyl or 5-7 membered heterocycloalkyl, the 5-7 membered cycloalkyl or 5-7 membered heterocycloalkyl is optionally substituted by R, and the




number of R is 1, 2 or 3; then the moiety


15. The compound, the (*R*)-isomer thereof, the (*S*)-isomer thereof or the pharmaceutically acceptable salt thereof as defined in claim 1, 11, 13 or 14, wherein the R₆ is selected from H, F, Cl,



16. The compound, the (*R*)-isomer thereof, the (*S*)-isomer thereof or the pharmaceutically acceptable salt thereof as defined in claim 1 or 2, wherein the R₇ is selected from H, F, Cl, Br, I, OH,




17. The compound, the (*R*)-isomer thereof, the (*S*)-isomer thereof or the pharmaceutically acceptable salt thereof as defined in claim 16, wherein the R₇ is selected from H, F, Cl, Br, I, OH,




18. The compound, the (*R*)-isomer thereof, the (*S*)-isomer thereof or the pharmaceutically acceptable salt thereof as defined in claim 1 or 2, wherein the ring A is selected from piperidyl which is optionally substituted by R, and the number of R is 1, 2 or 3.

19. The compound, the (*R*)-isomer thereof, the (*S*)-isomer thereof or the pharmaceutically


acceptable salt thereof as defined in claim 18, wherein the moiety



20. The compound, the (*R*)-isomer thereof, the (*S*)-isomer thereof or the pharmaceutically




acceptable salt thereof as defined in claim 1 or 2, wherein the moiety



selected from

21. The compound, the (*R*)-isomer thereof, the (*S*)-isomer thereof or the pharmaceutically

acceptable salt thereof as defined in any one of claims 1-11 or 16-17, which is selected from




wherein,

D is selected from -N(R₂)-, -N⁺(O⁻)(R₂)- and -C(R₃)(R₄)-;

r, m, R₁, R₂, R₃, R₄, R₅, R₆ and R₇ are as defined in claims 1-9 or 16-17;

the carbon atom with "*" is a chiral carbon atom and exists in the form of (*R*) or (*S*) single enantiomer or enriched in one enantiomer.

22. The compound, the (*R*)-isomer thereof, the (*S*)-isomer thereof or the pharmaceutically acceptable salt thereof as defined in claim 21, which is selected from



wherein,


D is selected from -N(R₂)-, -N⁺(O⁻)(R₂)- and -C(R₃)(R₄)-;

r, R₁, R₂, R₃, R₄ are as defined in claims 1-7;


the carbon atom with "*" is a chiral carbon atom and exists in the form of (*R*) or (*S*) single enantiomer or enriched in one enantiomer.

23. The compound, the (*R*)-isomer thereof, the (*S*)-isomer thereof or the pharmaceutically


acceptable salt thereof as defined in claim 22, wherein the moiety



is selected from



24. The compound, the (*R*)-isomer thereof, the (*S*)-isomer thereof or the pharmaceutically acceptable salt thereof as defined in claim 22, which is selected from





wherein R₁, R₂, R₃, R₄ are as defined in claims 1-7;

the carbon atom with "*" is a chiral carbon atom and exists in the form of (*R*) or (*S*) single


enantiomer or enriched in one enantiomer.

25. A compound as shown below, an (*R*)-isomer thereof, an (*S*)-isomer thereof or a pharmaceutically acceptable salt thereof, which is selected from







26. The compound, the (*R*)-isomer thereof, the (*S*)-isomer thereof or the pharmaceutically acceptable salt thereof as defined in claim 25, which is selected from









27. Use of the compound or the pharmaceutically acceptable salt thereof as defined in any one of claims 1-26 in the manufacture of a medicament for treating tumor.

28. The use as defined in claim 27, wherein the medicament is used for the treatment of solid tumors.